Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)

October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential

MIAMI - Oct. 15, 2026 - PRLog -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP is approaching a pivotal period in its development, with a new FDA update putting its preservative-free ketamine program firmly in focus. On October 15, 2026, the company announced that the U.S. Food and Drug Administration had issued a Discipline Review Letter requesting minor changes to the product's submitted labeling. The FDA also requested sample labeling incorporating the proposed proprietary product name, which remains under review, ahead of the application's November 10, 2026, goal date. Importantly, NRx reported that all requested labeling changes were classified as minor, while final manufacturing process validation runs are underway to support potential commercialization. The announcement provides investors with a defined upcoming regulatory milestone and adds to a broader corporate story encompassing pharmaceutical development, advanced brain stimulation technology, and government-funded clinical research. <Cite refs={["turn117971news13","turn117971search7"]}/>

FDA Update Places November 10 in the Spotlight

NRx's latest announcement marks another important step in its efforts to bring preservative-free intravenous ketamine to the U.S. market through an Abbreviated New Drug Application (ANDA). Ketamine is an established medicine used in clinical settings, and NRx has emphasized the potential value of a preservative-free preparation amid concerns about hospital supply reliability.

The FDA's October 15 letter requests minor labeling revisions and sample labels featuring the proposed product name. This follows the agency's September 15 decision to reclassify an earlier application amendment related to the drug vial from a major amendment to a minor amendment, setting the November 10 GDUFA goal date.

For investors, several developments stand out:

• Minor labeling requests: The company reports that all changes requested in the latest letter were classified as minor.
• November 10 goal date: This remains the announced FDA review milestone for the ANDA.
• Manufacturing readiness: NRx says final manufacturing process validation runs are underway.
• Product-name review: The proposed proprietary name remains under FDA review.

The distinction between progress and approval remains essential. The latest communication does not constitute FDA approval, and the agency's final decision remains pending. Nevertheless, the combination of a defined review date, remaining labeling work, and manufacturing preparation provides a concrete set of milestones for investors to follow. <Cite refs={["turn117971news13","turn117971search7"]}/>

An $11.18 Million DARPA Contract Adds a Major Research Catalyst

NRx's development strategy extends well beyond its immediate ketamine opportunity. On September 30, 2026, its subsidiary NRx Defense Systems announced an approximately $11.18 million prime contract from the Defense Advanced Research Projects Agency (DARPA) to evaluate SPARC-TMS, a clinical research program combining robotic, neuronavigated transcranial magnetic stimulation (TMS) with NRX-101, NRx's investigational oral drug candidate.

The trial is designed to evaluate whether a single-day treatment protocol can help patients with treatment-resistant depression. It brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.

The contract has an 18-month performance period. Approximately $6.7 million was initially obligated, with additional funding dependent on appropriations and the exercise of contract options. Payments are tied to program milestones.

This arrangement offers an important opportunity to advance research while supporting a potentially differentiated treatment approach. If the trial produces encouraging results, it could help establish a foundation for further development of NRX-101 alongside TMS. The clinical results, however, will determine whether the approach can support subsequent regulatory applications.

HOPE Therapeutics Connects Research With Advanced Treatment Technology

NRx's subsidiary HOPE Therapeutics is another important part of the company's strategy. On September 11, NRx announced that HOPE was preparing to deploy Zeta Surgical's FDA-cleared robotic TMS navigation system at its Florida clinics.

The technology is designed to help clinicians position TMS equipment using advanced navigation software. Its potential role in delivering consistent treatment positioning complements the company's interest in combining pharmaceutical candidates with technology-enabled psychiatric care.

This creates a connection between NRx's research pipeline and an operating clinical network. HOPE's facilities may provide experience with advanced treatment delivery and a platform for participating in clinical programs, subject to the applicable study requirements.

Together, the robotic TMS initiative and SPARC-TMS contract give investors another area to monitor as NRx works to develop differentiated approaches for difficult-to-treat depression. <Cite refs={["turn117971search9","turn117971search10"]}/>

NRX-100 and NRX-101 Anchor the Pharmaceutical Pipeline

NRx's two principal drug-development programs address different opportunities.

NRX-100 is the company's preservative-free intravenous ketamine product. In addition to its ANDA, NRx has initiated a separate New Drug Application pathway for potential use in treating suicidal ideation in patients with depression, including bipolar depression. The company has reported FDA Fast Track Designation for this development program.

NRX-101 is an investigational oral combination of D-cycloserine and lurasidone. NRx has pursued its development for serious depression-related conditions, including suicidal bipolar depression, and has reported FDA Breakthrough Therapy Designation for that indication.

These programs offer different potential catalysts and follow distinct regulatory pathways. The near-term focus is the preservative-free ketamine ANDA, while the broader pipeline provides additional opportunities for clinical and regulatory progress.

The SPARC-TMS program is particularly notable because it could explore NRX-101 in combination with robotic brain stimulation for treatment-resistant depression, potentially opening a separate avenue for future development if supported by clinical evidence. <Cite refs={["turn117971news13","turn117971search9"]}/>

Manufacturing Preparation and Financial Resources

NRx has previously reported commercial-scale manufacturing preparations for preservative-free ketamine, including plans to build launch inventory. In its August 17, 2026, second-quarter update, the company described plans for approximately five million doses of launch inventory and additional production following a potential launch.

The company also reported completing an underwritten public offering that generated approximately $22.3 million in gross proceeds. On June 30, 2026, NRx reported approximately $26.7 million in cash and cash equivalents and stated that its resources were expected to support at least one year of operations.

These earlier disclosures provide useful context as the company approaches its next regulatory milestone. Manufacturing validation, cash utilization, additional financing needs, and commercial execution will all be important considerations if approval is obtained. The reported financial position reflects the company's position at the end of the second quarter, rather than a guarantee of its current cash balance or future funding requirements. <Cite refs={["turn117971search10"]}/>

Key NRXP Developments to Watch

• October 15, 2026: FDA requests minor labeling changes for preservative-free ketamine.
• November 10, 2026: Announced GDUFA goal date for the ketamine ANDA.
• Manufacturing: Final process validation runs are underway, according to the company.
• DARPA contract: Approximately $11.18 million awarded for the SPARC-TMS research program.
• HOPE Therapeutics: Continued development of robotic TMS capabilities.
• NRX-101: Ongoing development of an investigational treatment for serious depression-related conditions.

The Bottom Line: A Significant Period for NRx Pharmaceuticals

NRx Pharmaceuticals is advancing several interconnected opportunities in neuroscience and mental health, with the preservative-free ketamine review serving as its most immediate regulatory catalyst.

Today's FDA announcement provides a clearer view of the remaining labeling work ahead of the November 10 goal date. At the same time, the DARPA-funded SPARC-TMS program, HOPE Therapeutics' technology initiatives, and the broader NRX-100 and NRX-101 pipeline give investors additional developments to follow.

For more information on $NRXP visit: https://www.nrxpharma.com and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: [email protected]
Phone: (917) 653-5122
Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website


Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP) | More news from this source

Press release distribution by PRLog